Back to CVE records
Medium 6.3HealthcarePublished May 24, 2018

CVE-2018-10595A vulnerability in ReadA version 1.1.0.2 and previous allows an authorized user with access to a privileged account on a BD Kiestra system (Kiestra TLA, Kiestra WCA, and InoqulA+ specimen processor)…

Updated under an hour ago ()

Does this affect you?

It affects Becton, Dickinson and Company Kiestra and InoqulA systems and 3 other products. Add what you run to find out whether that includes you.

EPSS puts the chance of exploitation in the next 30 days at 0.41%, higher than 34% of scored CVEs.

A vulnerability in ReadA version 1.1.0.2 and previous allows an authorized user with access to a privileged account on a BD Kiestra system (Kiestra TLA, Kiestra WCA, and InoqulA+ specimen processor) to issue SQL commands, which may result in loss or corruption of data.

CVSS
6.3 MEDIUM (v3.0, NVD)CVSS:3.0/AV:A/AC:H/PR:H/UI:R/S:U/C:H/I:H/A:H
Weakness (CWE)
CWE-356
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
0.41% (percentile 34)
Assigned by
icscert
NVD analysis
Modified
Record last updated
Sep 17, 2024
First seen by InfoSec Signals
Oct 12, 2026

Affected products

Affected products
Becton, Dickinson and Company Kiestra and InoqulA systems
becton_dickinson_and:kiestra_and_inoqula_systems (from the name)
Kiestra TLA, Kiestra WCA, and InoqulA+ specimen processor using ReadA Overview version 1.1.0.2 and previous.
CNA record
bd database_manager
bd:database_manager
3.0.1.0
NVD
bd performa
bd:performa
through 3.0.0.0
NVD
bd reada
bd:reada
through 1.1.0.2
NVD

References

  • x-refsource-confirm, vendor-advisory
  • x-refsource-misc, third-party-advisory, us-government-resource

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.